Advanced or recurrent esophageal cancer
Conditions
Interventions
docetaxel cisplatin 5-Fu
Sponsors
gifu University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with evaluable lesions or measurable Patients have been identified with esophageal cancer histologically Case found that there is no effect of previous treatment.
Exclusion criteria
Exclusion criteria: Cases with (heart disease, interstitial pneumonitis or pulmonary fibrosis, and cirrhosis of the liver) complications serious. patients with serious infections Patients with edema required Treatment Cases with non-pleural effusion control, ascites Patients with a history of drug hypersensitivity serious. Cases there is a possibility that pregnant women, pregnant and lactating women. Cases is determined participation in the test is difficult and complicated by psychiatric symptoms or psychosis Patients undergoing (oral or intravenous) systemic continuous administration ofsteroid Cases attending physician was deemed inappropriate In carrying out Other, this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint estimate the optimal dose of docetaxel in combination therapy in CF. consider kind of side effects, the severity. Secondary endpoints To examine the anti-tumor effect and incidence of adverse events. | — |
Countries
Japan
Contacts
Public ContactYoshihiro Tanaka
Gifu University Surgical Oncology
Outcome results
None listed